By.Damba Rogers
Following the recalling of 20,000 doses of Hepatitis B drugs from the market by CIPLA Quality chemicals, the CEO of the drug manufacturing company, Nevin Bradford confirms that they will be replacing all the recalled doses of Hepatitis B drugs Tenofovir 300mg in the 1st week of October 2019.
News circulated
over the weekend that CIPLA has
recalled Tenofavir a drug that
treats Hepatitis B on the recommendation of national drug authority that the
drug lacked some specification to meet the desired efficacy and this worried
masses.
But, Nevin says, Cipla undertook a voluntary
recall of several batches of its Texavir,
a tenofovir based drug adding that
the recall is part of the quality management system for medicines adding that it’s
a global practice required of every drug manufacturer as per good manufacturing
practices.
He then
assures the public and those on treatment that there was no efficacy issue with
the recalled batch and confirms that they will be sending 20,000 doses of Tenofovir to the market by the 1st week
of October.
He also pledges that CIPLA is committed to producing quality drugs for both Ugandan and external markets as well as standard products that meet the stipulated by the various local, regional and international drug regulatory agencies.
END